Loading...
CRON logo

Cronos Group Inc.NasdaqGM:CRON Stock Report

Market Cap US$947.7m
Share Price
US$2.51
US$3.04
17.5% undervalued intrinsic discount
1Y42.1%
7D0.4%
Portfolio Value
View

Cronos Group Inc.

NasdaqGM:CRON Stock Report

Market Cap: US$947.7m

Cronos Group (CRON) Stock Overview

A cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. More details

CRON fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for CRON from our risk checks.

CRON Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

US$21.53
67.8% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67

Cronos Group Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cronos Group
Historical stock prices
Current Share PriceCA$2.53
52 Week HighCA$3.43
52 Week LowCA$1.60
Beta1.24
1 Month Change-2.69%
3 Month Change-6.30%
1 Year Change42.13%
3 Year Change36.76%
5 Year Change-71.22%
Change since IPO1,433.33%

Recent News & Updates

Cronos: Geographic Expansion Backed By A Strong Balance Sheet

Feb 25

Recent updates

Cronos: Geographic Expansion Backed By A Strong Balance Sheet

Feb 25

Cronos Reports Improved Q4-2024 Financials With Revenues From GrowCo

Mar 06

Cronos Group Is Probably Undervalued As Liquidity Swells

Dec 05

Buy Cronos Stock Before It Surges Higher

Aug 20

Cronos Group: An Intriguing Value Opportunity

Jun 17

Cronos Stock: Attractive Now With Cannabis Legalization In Germany

Mar 04

Cronos Group: Flush With Cash And Trading Below Book Value

Feb 11

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Aug 09

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Aug 01

Cronos Group: High Hurdles

May 11

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

Mar 01

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Feb 22

Cronos Group: Still No Reason To Own

Jan 22

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

Nov 08

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

Aug 30

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Jul 12

Shareholder Returns

CRONUS PharmaceuticalsUS Market
7D0.4%2.9%-0.3%
1Y42.1%29.1%16.1%

Return vs Industry: CRON exceeded the US Pharmaceuticals industry which returned 29.1% over the past year.

Return vs Market: CRON exceeded the US Market which returned 16.1% over the past year.

Price Volatility

Is CRON's price volatile compared to industry and market?
CRON volatility
CRON Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.1%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.3%

Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CRON's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a610Mike Gorensteinthecronosgroup.com

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Cronos Group Inc. Fundamentals Summary

How do Cronos Group's earnings and revenue compare to its market cap?
CRON fundamental statistics
Market capUS$947.72m
Earnings (TTM)-US$9.45m
Revenue (TTM)US$146.59m
6.5x
P/S Ratio
-101.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRON income statement (TTM)
RevenueUS$146.59m
Cost of RevenueUS$88.19m
Gross ProfitUS$58.40m
Other ExpensesUS$67.85m
Earnings-US$9.45m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.025
Gross Margin39.84%
Net Profit Margin-6.44%
Debt/Equity Ratio0%

How did CRON perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/02 23:28
End of Day Share Price 2026/04/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cronos Group Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein